References
- Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat. 2011;18(Suppl.1):1–16.
- Toy M, Onder FO, Wörmann T, et al. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis. 2011;11:337.
- Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. doi:10.1155/2012/145754 .
- Yüksel F, Türkkan D, Yüksel I, et al. Fatty liver disease in an autopsy series of children and adolescents. Hippokratia. 2012;16(1):61–65.
- Arslan N, Büyükgebiz B, Oztürk Y, et al. Fatty liver in obese children: prevalence and correlation with anthropometric measurements and hyperlipidemia. Turk J Pediatr. 2005;47:23–27.
- Celebi S, Ataseven H, Mengucuk E, et al. Epidemic features of nonalcoholic fatty liver in urban community of Elazıg. Akademik Gastroenteroloji Dergisi. 2006;5(1):41–46.
- Uyanikoglu A, Coskun M, Binici DN, et al. The frequency of hepatosteatosis in inactive hepatitis B carries. Viral Hepat J. 2011;17(2):62–65.
- Demir ME, Aydogan T, Pamukcu M, et al. Ultrasound evaluation of metabolic syndrome patients with hepatosteatosis. J Clin Exp Investig. 2013;4(2):153–158.
- Lesmana LA, Lesmana CRA, Pakasi LS, et al. Prevalence of hepatic steatosis in chronic hepatitis B patients and ıts association with disease severity. Acta Med Indones. 2012;44:1.
- Hübscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006;49:450–465.
- Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am. 1995;24(4):759–786.
- Incedayı M, Pekkafali MZ, Sildiroglu HO, et al. Sonographic and histopathological correlation in diffused fatty liver. Anatol J Clin Investig. 2012;6(1):1–5.
- Kara M, Erdal M. A public health issue that increased prevalence: non-alcoholic fatty liver disease. TAF Prev Med Bull. 2014;13(1):65–76.
- Wang -C-C, Hsu C-S, Liu C-J, et al. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol. 2008;23:779–782.
- Poortahmasebi V, Alavian SM, Keyvani H, et al. Hepatic steatosis: prevalence and host/viral risk factors in Iranian patients with chronic hepatitis B infection. Asian Pac J Cancer Prev. 2014;15(9):3879–3884.
- Zheng R, Xu C, Jiang L, et al. Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis. Int J Med Sci. 2010;7(5):272–277.
- Altiparmak E, Koklu S, Yalinkilic M, et al. Viral and host causes of fatty liver in chronic hepatitis B. World J Gastroenterol. 2005;11(20):3056–3059.
- Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology. 2006;44(6):1648–1655.
- Hu K-Q, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004;40:147–154.
- Patel JH, Cobbold JFL, Thomas HC, et al. Hepatitis C and hepatic steatosis. Q J Med 2010;103:293–303.
- Fan J-G, Chitturi S. Hepatitis B and fatty liver: causal or coincidental? J Gastroenterol Hepatol. 2008;23:679–681.
- Wu D, Li H, Xiang G, et al. Adiponectin and its receptors in chronic hepatitis B patients with steatosis in China. Hepat Mon. 2013;13(4):e6065.
- Estakhri A, Sari AA, Nedjat SN, et al. The effect of NAFLD (non-alcoholic fatty liver disease) on long-term outcome of chronic hepatitis B in Iranian patients. Open J Gastroenterol. 2012;2:18–21.
- Yilmaz B, Koklu S, Buyukbayram H, et al. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis. Afr Health Sci. 2015;15:3.
- Ben Slama Trabelsi A, Ksiaa M, Souguir A, et al. Hepatic steatosis in chronic hepatitis B: prevalence, risk factors, and impact on fibrosis and therapeutic response. Europe PMC. 2013;91(7):431–434.